Cynvenio, Cure Forward Partner
News Jun 19, 2015
The partnership will leverage Cynvenio's ClearID liquid biopsy test, which detects tumor cells from blood samples. The test aids clinicians in choosing optimal therapies for their patients and can accelerate patient enrollment in clinical trials.
Patients enrolled in Cure Forward and tested with ClearID will have direct access to their data. The test must be ordered by a physician.
"The barriers to personalized medicine are too high for too many patients," Cure Forward CEO Martin Naley said in a statement. "We help people find innovative testing options like the ClearID test from Cynvenio and then use those results to be more effective champions of their own care."
Cure Forward is newly formed and also forged a partnership with Paradigm.
Cynvenio announced on Wednesday it raised $25.5 million in a Series B financing round.
Schizophrenics' Blood Contains RNA From More MicrobesNews
The blood of schizophrenia patients features genetic material from more types of microorganisms than that of people without the debilitating mental illness, research at Oregon State University has found. What’s not known is whether that’s a cause or effect of the severe, chronic condition that strikes about one person in 100.READ MORE
Faulty Gene Leads to Alcohol-Induced Heart FailureNews
A faulty gene interacts with alcohol to accelerate heart failure in susceptible patients, a study suggests. This dangerous interaction can occur even when only moderate amounts of alcohol have been consumed.READ MORE